Please assess the completion status of the following clinical trial:

Trial Title: Pediatric ACTION3 (Identify, Treat, Control): Effectiveness of Adding Montelukast in Pediatric Subjects With Uncontrolled Asthma (0476-385)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patient Is Diagnosed With Asthma For At Least 6 Months~* Patient's Peak Expiratory Flow (PEF) Is 80% Of Predicted Value (Appendix 10)~* Patient Is Currently Untreated, Or Patient Is A User Of Short-Acting 2-Agonist On An As-Needed Basis, Or Patient Is A User Of Ics At Any Dosage~* Physician And/Or Patient Are Dissatisfied With Current Controller Therapy, Or Patient Is Reluctant To Take Ics Therapy, Or Patient Is Insufficiently Controlled Due To Non-Adherence With Current Therapy Through The Preceding 6 Weeks~Exclusion Criteria:~* As Per Canadian Guidelines, Patient Is On A Laba Alone (Formoterol (Oxeze), Salmeterol (Serevent)) Or A Combination Product (Advair Or Symbicort)~* Patient Is Well Controlled, Adherent And Satisfied With Current Controller Therapy

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 14 Years
- Healthy Volunteers: f

Study Arms:
- Montelukast (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).